Blog
From rare to common: The time to tackle rare diseases is now
As a paediatrician working in drug development, mother of a child with a rare disease, and founder of a medical research charity, Dr Harriet Holme understands the complexities of the rare disease landscape. Here, she argues that while balancing the interests of various stakeholders is essential, we cannot afford to delay action in the rare disease space any longer.
Preparing for the Inflation Reduction Act – Part 3: The impact on valuation, business development, mergers and acquisitions
What does the US Inflation Reduction Act (IRA) mean for indication selection, and how could this alter lifecycle management? In the second instalment of this three-part series, Emma Tinsley, Chief Executive Officer of Weatherden, tells us about the key strategic considerations for biopharma companies in the post-IRA era.
Preparing for the Inflation Reduction Act - Part 2: The IRA’s impact on indication selection, clinical development and regulatory strategy, and lifecycle management
What does the US Inflation Reduction Act (IRA) mean for indication selection, and how could this alter lifecycle management? In the second instalment of this three-part series, Emma Tinsley, Chief Executive Officer of Weatherden, tells us about the key strategic considerations for biopharma companies in the post-IRA era.
Preparing for the Inflation Reduction Act - Part 1: What is the IRA and why should you care?
In this first part of a three-part series Emma Tinsley, Chief Executive Officer of Weatherden explains what the IRA is, how it affects drug pricing, and why biotech and pharma companies – including those outside the US – need to take notice.
>200 companies
We have advised, worked with and supported dozens of funds and biotechs.
>500 million plus
Our input is benefitting patient populations worldwide.
>25 billion USD
Our repeat and long-term clients have realised significant value gains since we became involved in their programmes.